GA29144: A Phase III, Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction and Maintenance Treatment for Patients with Moderately to Severely Active Crohn’s Disease

May 22, 2015
Gastroenterology - Stomach
Principal Investigator: Nirmal Kaur, MD
The purpose of this research study is to determine whether etrolizumab is a safe and effective treatment for patients with moderately to severely active Crohn’s disease.
Please contact us for a full list of criteria.